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IMPORTANCE There is a high prevalence of obesity in psychiatric patients, possibly leading to
metabolic complications and reducing life expectancy. The CREB-regulated transcription
coactivator 1 (CRTC1) gene is involved in energy balance and obesity in animal models, but its
role in human obesity is unknown.
OBJECTIVE To determine whether polymorphisms within the CRTC1 gene are associated with
adiposity markers in psychiatric patients and the general population.
DESIGN, SETTING, AND PARTICIPANTS Retrospective and prospective data analysis and
population-based samples at Lausanne and Geneva university hospitals in Switzerland and a
private clinic in Lausanne, Switzerland. The effect of 3 CRTC1 polymorphisms on bodymass
index (BMI) and/or fat mass was investigated in a discovery cohort of psychiatric outpatients
taking weight gain–inducing psychotropic drugs (sample 1, n = 152). The CRTC1 variant that
was significantly associated with BMI and survived Bonferroni corrections for multiple
comparison was then replicated in 2 independent psychiatric samples (sample 2, n = 174 and
sample 3, n = 118) and 2 white population-based samples (sample 4, n = 5338 and sample 5,
n = 123 865).
INTERVENTION Noninterventional studies.
MAIN OUTCOME ANDMEASURE Difference in BMI and/or fat mass between CRTC1 genotype
groups.
RESULTS Among the CRTC1 variants tested in the first psychiatric sample, only rs3746266A>G
was associated with BMI (Padjusted = .003). In the 3 psychiatric samples, carriers of the
rs3746266 G allele had a lower BMI than noncarriers (AA genotype) (sample 1, P = .001;
sample 2, P = .05; and sample 3, P = .0003). In the combined analysis, excluding patients
taking other weight gain–inducing drugs, G allele carriers (n = 98) had a 1.81–kg/m2 lower BMI
than noncarriers (n = 226; P < .0001). The strongest association was observed in women
younger than 45 years, with a 3.87–kg/m2 lower BMI in G allele carriers (n = 25) compared
with noncarriers (n = 48; P < .0001), explaining 9% of BMI variance. In the population-based
samples, the T allele of rs6510997C>T (a proxy of the rs3746266 G allele; r2 = 0.7) was
associated with lower BMI (sample 5, n = 123 865; P = .01) and fat mass (sample 4, n = 5338;
P = .03). The strongest association with fat mass was observed in premenopausal women
(n = 1192; P = .02).
CONCLUSIONS AND RELEVANCE These findings suggest that CRTC1 contributes to the genetics
of human obesity in psychiatric patients and the general population. Identification of high-risk
subjects could contribute to a better individualization of the pharmacological treatment in
psychiatry.
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A high prevalence of obesity has been described in psy-chiatric patients, with reported increased mortality,1-3due not only to the underlying illness and related co-
morbidities,butalsotothepharmacological treatment.4-8Atypi-
cal antipsychotics and other drugs, such as themood stabiliz-
ers lithiumandvalproate,9-12 can inducesubstantialweightgain
in selected patients. This is a serious adverse effect consider-
ingthatobesitycanleadtometaboliccomplicationssuchasdys-
lipidemia, type 2 diabetes, and cardiovascular disease, which
may ultimately reduce life expectancy by several years.13-15
Psychiatric, psychological, sociodemographic, andbehav-
ioral factors, as well as heritability, have been shown to influ-
ence individual susceptibility to overweight or obesity, both
in the general population16-20 and in psychiatric patients be-
fore and after treatment with potentially weight gain–
inducing psychotropic drugs.21-26 Genome-wide association
studies conducted todateonlyexplaina small fractionofbody
mass index (BMI) heritability20 andmore obesity susceptibil-
ity genes remain to be discovered.Whereas genome-wide as-
sociation study meta-analyses have been extremely valu-
able, other approaches are also needed to further understand
the biology of human obesity.
Obesity results from an imbalance between energy intake
and energy expenditure. One component of energy balance is
the control of food intake that is achieved at least in part via
highly specialized neurons located in the hypothalamus and
modulated by peripheral metabolic signals.27,28 Recent re-
search has begun to unravel some of the neuronal pathways
regulating food intake, but theexactmechanismsbywhichpe-
ripheral signals are sensed in thehypothalamusandhowthese
signals are then integrated and translated into a coordinated
peripheral response are still unclear. We and others have re-
cently shown thatmice lacking theCREB-regulated transcrip-
tion coactivator 1 (CRTC1) gene eatmore and have less energy
expenditure thanwild-typemice, thusdevelopinganobese fea-
ture, including obesity-related metabolic complications, un-
dernormal diets.29,30 These results suggest thatCRTC1 is play-
ingamajor role in thehypothalamic control of food intake.The
CRTCfamily (also calledTORCs) comprises 3members,CRTC1,
CRTC2, and CRTC3, that are expressed in different tissues.31
CRTC1 ismainlyexpressed in thebrain29-33where itmaymodu-
late leptin anorexic effect in thehypothalamus. In the cell, the
inactive phosphorylated form of CRTC1 is sequestered in the
cytoplasm, and its migration to the nucleus requires the con-
comitant activation of the phosphatase calcineurin and the
inactivation of kinases of the 5′ adenosine monophosphate-
activated protein kinase (AMPK) family.34 Interestingly, anti-
psychoticsmay increaseweightby selective andpotent stimu-
lation of hypothalamic AMPK,35 which has been shown to
regulate food intake and reverse the actions of the anorexi-
genichormone leptin.36AMPKstimulationparallels theorexi-
genic actions of thedrugs,with clozapine andolanzapinepro-
ducing the most marked effects. The obese phenotype of
CRTC1-deficient mice, the regulation of CRTC1 activity by
AMPK, the hypothalamic activation of this kinase by antipsy-
chotics, and the high prevalence of obesity in psychiatric pa-
tients prompted us to examine the role of the CRTC1 gene in
human obesity especially in the psychiatric population.
Methods
Psychiatric Samples
Written informed consentwas givenby all subjects or their le-
gal representatives. The studies were approved by the ethics
committee of their corresponding institutions. White sub-
jects treatedwith antipsychotics and/ormoodstabilizerswere
first recruited from outpatient psychiatric centers of Geneva
UniversityHospital. The associationof theCRTC1variantwith
BMI (calculatedasweight inkilogramsdividedbyheight inme-
ters squared) was then replicated in 2 independent samples
from Lausanne University Hospital.
Samples 1 and 3
Samples 1 (n = 152) and 3 (n = 118) are 2 retrospective studies;
studyof sample 1wasconducted inoutpatientpsychiatric cen-
ters of Geneva University Hospital from 2006 to 2008, while
study of sample 3 was conducted in 2 outpatient psychiatric
centers of Lausanne, Switzerland (Lausanne University Hos-
pital andaprivatepsychiatric center), from2010 to2011.Treat-
ment formore than3months (sample 1) and9months (sample
3)withclozapine,olanzapine,quetiapine, risperidone, lithium,
and/or valproate (sample 1 and sample 3) and/or aripiprazole,
amisulpride, and/or sertindole (sample 3)were indicatedas in-
clusion criteria. Seventy-twopercent and 52%of sample 1 and
sample 3, respectively, had already received other psychotro-
pic treatments before the current treatment. At inclusion of
both samples, body weight and height were measured for all
patients,while theirbaselineweightbefore the initiationof the
current treatment and/or at different times during treatment
was collected fromthemedical file orwas self-reported (base-
line weight was self-reported in 76% of sample 1 and 78% of
sample 3). In the subset of patients for whom both data were
available, self-reportedweightwas in agreementwithweight
obtained fromthemedical files (n = 29; r2>0.9 for sample 1 and
n = 39; r2>0.8 forsample3). Inadditionto thebaselineandmea-
suredweight at inclusion, 54% and 29% of patients in sample
1 and sample 3, respectively, had at least 1 additional re-
corded weight from the medical files during the study dura-
tion that was also included in the statistical analysis. Finally,
self-reportedweights before the initiation of the first psycho-
tropic treatment were also obtained for most of the patients
(98% and 95% for sample 1 and sample 3, respectively). Both
samples consistedof a single visit performedduring theusual
clinical psychiatric follow-up. If the patient was taking more
than 1 psychotropicmedication, themedicationwith the lon-
gest treatmentdurationwasentered in themodelandtheother
potentialweightgain–inducingdrugsof interest, includingtypi-
cal andatypical antipsychoticsandmoodstabilizers,wereclas-
sified as other possible weight gain–inducing drugs, listed in
eTable 1 in Supplement.
Sample 2
A follow-up study has been ongoing since 2007 in all psychi-
atricwardsofLausanneUniversityHospital.Onehundredsev-
enty-fourpatientswithnewlyprescribedaripiprazole, amisul-
pride, clozapine, olanzapine, quetiapine, risperidone,
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sertindole, and/or lithium or valproate were recruited. Sixty-
six percent had already received other psychotropic treat-
ments and were included in the study after having switched
medication. No washout period was required. Weights and
clinical variableswereprospectively recordedat several points
during the first 12 months according to published recom-
mended monitoring guidelines (ie, before starting the cur-
rentpsychotropicdrugs, thenatmonths 1, 2, 3, 6, 9, and12).37,38
At the baseline and follow-up visits, the severity of disorders
was rated using the Clinical Global Impression rating scale,
which is a commonly used measure of psychotic symptom
severity.39 This scale measured the severity of the disorder at
each visit relative to the baseline state at the introduction of
the newly studied psychotropic drug, rather than the onset
of the disorder. For statistical analyses, patients were
dichotomized according to this scale into moderately to
severely ill vs mildly ill or not ill at all. If the patient was
taking more than 1 psychotropic medication, the newly
introduced studied drug was considered as the main psycho-
tropic medication, and the other potential weight gain–
inducing drugs of interest, including typical and atypical
antipsychotics and mood stabilizers, were classified as other
possible weight gain–inducing drugs.
Population-Based Sample (Cohorte Lausannoise)
Participants in the population-based sample (Cohorte Laus-
annoise [CoLaus])were recruitedbetween June2003andMay
2006, as previously described.40
Genetic Investigation of Anthropometric Traits Consortium
The Genetic Investigation of Anthropometric Traits (GIANT)
consortiumperformedameta-analysis of genome-wide asso-
ciation study data with a discovery set of 123 865 individuals
of European ancestry from46 studies for height,41 BMI,20 and
waist to hip ratio.42
Genotyping and CRTC1 Polymorphisms
To our knowledge, no functional consequences of CRTC1 ge-
neticpolymorphismshavebeenreported inhumansuntil now.
ThreeCRTC1 single-nucleotidepolymorphisms (SNPs)werese-
lected in the psychiatric sample based on high frequencies of
theminor allele in their respective regions in white individu-
als: rs10402536G>A in intron 1, rs8104411C>T in the3′ untrans-
lated region (because the CRTC N- and C-terminal domains
were reported to contain CREB binding and transactivation
domains),31 and a third coding SNP (rs3746266A>G) that leads
to threoninetoalaninesubstitutionatposition328 (Thr328Ala).
The rs3746266A>G SNP, which was significantly associated
with BMI in psychiatric patients, was not genotyped in the
population-based samples. However, among the CRTC1 SNPs
genotyped in the latter samples, the intronicSNPrs6510997C>T
was found to be an adequate proxy (r2 = 0.7; D′ = 1) of
rs3746266A>G. In a second step, thepsychiatric sampleswere
genotyped for the proxy rs6510997C>T as well.
Psychiatricpatients’ genotypingwasperformedusingTaq-
Man allelic discrimination assay (Applied Biosystems). Geno-
typing for the CoLaus subjects was performed using the Af-
fymetrixGeneChipHumanMapping500Karraysetandweused
the Agilent SureSelect protocol for exome capture and the Il-
luminaGenomeAnalyzer2platformfor sequencing (details are
available in the eMethods at http://www.chuv.ch/psychiatrie
/dpc_home/dpc_infos/dpc_infos_organisation/dpc-cpn/dpc_cnp
_upcc_eng.htm).
Statistical Analysis
Psychiatric Sample
Univariate analyses were done using t tests. The association
of the 3CRTC1 SNPswithBMI in the first samplewas assessed
by fitting a generalized additivemixedmodel (GAMM)43,44 to
allow a smooth trend for the response in time based on mul-
tiple observations for each patient (using a thin plate regres-
sion spline basis) adjusting for age, sex, smoking status, cur-
rent psychotropic drug, and standardized dose. The P values
of these 3modelswere adjusted formultiple comparisons ac-
cording toBonferroni. Similarmodelswere applied to test the
association betweenCRTC1 rs3746266A>G (chosen according
to the analysis in sample 1) and BMI in samples 2 and 3. A ran-
domeffect at the subject levelwas also introduced to take the
dependence structure of observed data into account. The
GAMMswere fittedusing themgcvpackageofR (settingswere
fixed at package defaults); to be more conservative, the un-
certainty of estimated parameters was assessed by 1000
bootstraps45 at the subject level and resultswere similarwith
those gained by 10 000 bootstraps. Whenever the P value for
the 1000 bootstrap analysis was lower than .001 (P < .001),
10 000bootstrap analysiswas performed. Topreservehomo-
geneityof thecombinedsample,onlypatients in samples 1 and
3 with less than 24months of the current psychotropic treat-
ment were taken into account. Because of the small number
of individuals homozygous for the rs3746266 G allele (n = 6,
n = 10, and n = 4 for samples 1 (n = 152), 2 (n = 174), and 3
(n = 118), respectively), the associations were analyzed using
a dominant model.
Themodel is fittedonallobservationsofpatients, somodel
coefficients provide information on both the direction and
magnitude of the overall association between BMI and the
genotypes for thespecificperiodof treatmentstudied.Thepsy-
chotropic drugs were classified according to their therapeu-
tic class (antipsychotics vs mood stabilizers).46
Population-Based Studies
TheassociationsofCRTC1 rs6510997C>Twith adipositymark-
erssuchasBMI,weight,waistcircumference,andfatmasswere
analyzed using multiple linear regression with allele dosage
(additivemodeof actionof theTallele) inwhichpotential con-
founding factors such as age, sex, and smoking status were
added as covariates in the CoLaus study, while BMI was the
onlymarker analyzed in GIANT.We calculated the explained
variance of fat mass in CoLaus by comparing R2 from a re-
duced linear regression model, ie, a model including all co-
variates except rs6510997C>T, with R2 from a full model in-
cluding all covariates and rs6510997C>T.
All tests were 2-sided and a P value ≤.05 was considered
statistically significant.All the analyseswereperformedusing
Stata version 11 (StataCorp) and R version 2.11.1 software.47
Power analysis was conducted using Quanto software ver-
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sion 1.2.4 (2009; JamesGauderman, PhD,University of South-
ern California, Los Angeles).
Results
eTable 2 in Supplement shows characteristics of the 444 psy-
chiatric patients and 5338 participants of the CoLaus study.
Obesity prevalence was higher in the psychiatric samples as
comparedwith the CoLaus sample and findings derived from
other general Swiss populations40,48,49 particularly in psychi-
atric samples 1 and 3, which have longer treatment durations
and higher median age.
CRTC1 Polymorphisms and Psychiatric Samples
For the psychiatric sample 1, the influence of 3 polymor-
phismswithin theCRTC1 geneonBMIwas investigatedby fit-
ting a GAMM separately for each polymorphism:
rs10402536G>A (β = 0.025; Padjusted = .872), rs8104411C>T
(β = 0.133;Padjusted = .814), and rs3746266A>G (β = −2.125;Pad-
justed = .003). TheCRTC1polymorphismrs3746266A>Gwasas-
sociatedwith BMI and this polymorphismwas used for repli-
cation in psychiatric samples 2 and 3. eTable 3 in Supplement
shows genotype frequencies in the individual psychiatric
samples and the combined sample.
To eliminate anypossible causeofweight gain inducedby
other concomitant psychotropic and nonpsychotropic medi-
cations, we first analyzed patients taking only the main psy-
chotropic drugs with no other weight gain–inducing drugs
listed in eTable 1 in Supplement. A total of 336 psychiatric pa-
tients were thus investigated. The median BMI at the begin-
ning of the current psychotropic treatment was significantly
lower for carriers of the rs3746266 G allele as compared with
thosewithAAgenotypes in samples 1 (P = .03) and3 (P = .003),
butnot in sample 2 (P = .51), aswell as in the combined sample
(P = .0009) (eTable 4 in Supplement). The same associations
were observed with the current BMI at the end of the study
follow-upperiod (eTable4 inSupplement). eFigure 1 inSupple-
ment shows the BMI at different periods for carriers of the
CRTC1 rs3746266A>G genotype in the psychiatric samples.
However, no significant association was observed between
CRTC1 rs3746266A>G genotype and BMI before the initiation
of the firstpsychotropic treatment in samples 1 (n = 83;P = .43)
and3 (n = 83;P = .53) andbycombining them(n = 166;P = .46)
(eTable 4 in Supplement).
The GAMManalyses showed a significant association be-
tweenCRTC1 rs3746266A>GandBMI,withG carriers having a
2.13–kg/m2 lower BMI than those with the AA genotype in
sample 1 (P = .001; n = 105) (Table 1). Similar significant results
were found insample3 (P = .0003;n = 87) and in thecombined
sample (P < .0001; n = 324) and were borderline for sample 2
(P = .05; n = 140), with carriers of the G allele having a 3.64–,
1.81–, and 1.00–kg/m2 lower BMI as comparedwith carriers of
theAAgenotype, respectively (Table 1). Interestingly, after ad-
justment for the severity of thepsychiatric disorder in sample
2 (the severity ratingwasonly available in this sample),weob-
served an even stronger association between BMI and CRTC1
rs3746266A>G,withGallele carriers having a 1.5–kg/m2 lower
BMIthancarriersof theAAgenotype(P = .02;95%CI,0.12-2.87).
Astratifiedsexanalysis in thecombinedpsychiatric sample
(n = 176andn = 148 formenandwomen, respectively) showed
a significant associationofCRTC1 rs3746266A>G inboth sexes
with, however, the association being stronger in women
(Table 1). Because of thedifference in fat distribution and car-
diovascular risk factors in womenwith age, additional analy-
ses showed the strongest protective effect of the G allele in
women younger than 45 years, with a BMI decrease of 3.87
kg/m2 for the G allele carriers (n = 25) comparedwith carriers
withAAgenotypes (n = 48;P < .0001),whileno significant as-
sociation was found in women older than 45 years (n = 75;
P = .10). Similar significant results were obtainedwhen using
a threshold of 50 and 55 years (Table 1).
Table 1. Associations Between CRTC1 rs3746266 in a DominantModel and BMI Over Time in the 3 Separate Psychiatric Samples and the Combined
Samplea
rs3746266A>G Sample Size
BMI Difference Between
G and AA Carriers (95% CI) P Value
Explained
Variance,b %
Sample 1 105 2.13 (0.62 to 3.49) .001 3.5
Sample 2c 140 1.00 (−0.29 to 2.16) .05 1.0
Sample 3c 87 3.64 (1.65 to 5.38) .0003d 6.5
Combined samplee 324 1.81 (1.00 to 2.64) <.0001d 2.6
Men 176 1.34 (0.35 to 2.40) .007 1.7
Women 148 2.14 (0.82 to 3.46) .001 2.8
Women ≥45 y 75 1.24 (−0.56 to 3.09) .10 1.3
Women <45 y 73 3.87 (1.98 to 5.76) <.0001d 8.7
Women <50 y 107 2.44 (0.98 to 4.02) .0005d 4.1
Women <55 y 120 2.20 (0.78 to 3.69) .002 3.3
Abbreviation: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared).
a Results were obtained by fitting generalized additive mixedmodels for
patients with no other weight gain–inducing drugs (other than the studied
psychotropic drug), controlling for age, sex (whenever appropriate), smoking
status, current psychotropic drug, and standardized doses.
b Explained variance by the polymorphism percentage.
c Twomissing data.
d Ten thousand bootstraps were used for this analysis.
e To have similar treatment duration, only patients treated for up to 24months
were included.
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The influence of the other weight gain–inducing drugs
along with themain psychotropic drugs was also analyzed in
thewhole sample (n = 444) andBMI remainedsignificantly as-
sociatedwith theCRTC1 rs3746266A>Ggenotype in theGAMM
model (eTable 5 in Supplement).
eTable 6 in Supplement shows the association of the cal-
culated percentage of fat mass with the rs3746266A>G geno-
type in the combined psychiatric sample, with the strongest
effectobserved inwomenyounger than45years.Thus, in these
women, the polymorphism explains 9% and 10% of the vari-
ance in BMI and calculated percentage of fat mass, respec-
tively (Table 1 and eTable 6 in Supplement).
Nongenetic factors were also found to be associatedwith
BMI in theGAMMmodel. Indeed, age (0.09–kg/m2 increase in
BMI per year of age; P < .0001) and the type of psychotropic
medication (1.41–kg/m2 higher BMI in patients receiving an-
tipsychotics compared with mood stabilizers; P = .003) were
associatedwithBMI in thecombinedpsychiatric sample.These
2 factorswere consistently associatedwith BMI in each of the
psychiatric samples and in analyses stratified by sex. A posi-
tive association of BMI with the severity of the disorder was
observed for sample 2 as well, in which moderately to se-
verely ill patients had a 0.50–kg/m2 lower BMI than less se-
verely ill patients (P = .02),which couldbe explainedby lower
food intake in the severely ill patientsduring the follow-upvis-
its. Interestingly, by adding physical activity to the GAMM
model, nearly a 2–kg/m2 lower BMI was noticed for patients
doingmore than 60minutes of physical activity per day com-
paredwith lower levelsofphysicalactivities.Theseresultswere
consistent in the separate and combined psychiatric samples
(data not shown).
Data regarding appetite and physical activity were avail-
able at differentpoints in theprospective study (sample 2) and
at the inclusion time for samples 1 and 3. No significant asso-
ciation was found between these 2 variables and CRTC1
rs3746266A>G. More details are presented in the eMethods.
CRTC1 Polymorphisms in the General Adult Population
The rs6510997C>T SNPwas used as a proxy of rs3746266A>G
in thegeneral adultpopulation.Byanalyzing the rs6510997C>T
SNP in the psychiatric samples, we found the same associa-
tion with BMI as for rs3746266A>G, confirming that the for-
merSNPcanbeusedasaproxyof the latter (eTable7 inSupple-
ment). We also looked up the rs6510997C>T variant in the
GIANT consortium (n = 123 807 individuals)20 and found a
strong direction-consistent association with BMI. Each copy
of the T allele decreased BMI by 0.02 SD unit (P = .01).
Table 2 shows the adjusted fat mass values by CRTC1
rs6510997C>T in theCoLaus study.Thevaluesdecreased from
21.84 kg (SE, 0.11) to 21.48 kg (SE, 0.16) to 21.21 kg (SE, 0.47) in
carriers of theCC,CT, andTTgenotypes (n = 5338;P = .03), re-
spectively. After stratification by sex, no significant associa-
tion of this SNP with fat mass was observed in women
(n = 2808; P = .07) or men (n = 2530; P = .23). However,
rs6510997C>T was associated with fat mass in premeno-
pausal women (n = 1192; P = .02) but not postmenopausal
women (n = 1616; P = .66). Interestingly, the association of
rs6510997C>T with fat mass was stronger in premenopausal
women taking oral contraception (n = 224; P = .02), in whom
it explained 1.34% of fat mass variance, and was not signifi-
cant in premenopausal women who did not take oral contra-
ceptives, despite a larger sample size (n = 968;P = .12).Weob-
served no clear effect of postmenopausal hormonal therapy
on the reported associations.
Therewasnosignificant associationof rs6510997C>Twith
BMI (P = .68),weight (P = .76), orwaist circumference (P = .60)
in the overall CoLaus sample, neither in men (P > .50) nor
women (P > .50).
Using exome-sequencing data available for a subset
(n = 413) of the CoLaus individuals (eMethods), we identified
8 rare,possiblydamagingmissensevariants in theCRTC1gene,
according topredictions byPolyPhen.50Only 1 individualwas
homozygous for the minor allele at position 18 853 754 (Na-
tional Center for Biotechnology Informationbuild 37), andhis
sex- and age-corrected BMI was 38.0. Thus, rare BMI-
increasing CRTC1 variants with large effect may exist.
Discussion
Our results suggest a role for theCRTC1 gene in the regulation
of human bodyweight and fatmass, which is consistent with
data from animal models.29,30 The CRTC1 nonsynonymous
polymorphismrs3746266A>GwasassociatedwithBMI in 3 in-
dependentpsychiatric samples inwhich lowerBMIvalueswere
measured in carriers of the G allele compared with noncarri-
ers.Thesex-stratifiedanalysis in thecombinedsample showed
a protective effect for the G allele both in men and women.
However, the strongest and most clinically relevant associa-
tionwasobserved inwomenyounger than45years, forwhom
carriers of the G allele had a 3.87–kg/m2 lower BMI than non-
carriers.Additionally,wecalculated thepercentageof fatmass
usinga formulabasednotonlyonBMI,but alsoonageandsex,
2 factors that have profound impact on fat mass. The calcu-
lated fat mass was found to be significantly associated with
CRTC1 rs3746266A>G in the psychiatric samples, with direc-
tion-consistent results. Furthermore, the protective effect of
theTalleleof rs6510997C>T (aproxyof rs3746266A>G) against
fat accumulation was also observed in a large population-
based sample (CoLaus). The effect size of this association is
clinically relevant and in a consistent direction with the one
observed in the psychiatric cohorts. This effect was essen-
tially seen in premenopausal women and, more specifically,
inwomentakingcontraceptivepills. Finally, these resultswere
confirmed in 123 807 individuals from the GIANT consor-
tium, with the T allele being associated with lower BMI.
We foundno association of rs6510997C>TwithBMI in the
CoLaus population-based sample. Bodymass indexmay less
accurately capture adiposity than estimated fat mass using
bioimpedance.51,52 In CoLaus, fat mass enabled capture of 3
timesmore subjectswithhigh cardiovascular risk thanBMI.52
TheCoLaus sample is better powered to detect an association
of the rs6510997C>T SNPwith fatmass (62%power for a vari-
ant explaining0.06%of fatmass variance) thanwithBMI (11%
and18%power foravariantexplaining0.01%and0.02%ofBMI
variance, respectively), whereas a 20-fold larger population-
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basedsampleused in theGIANTconsortiumhasenoughpower
to observe an associationwith BMI (94% and >99%power for
a variant explaining0.01%and0.02%ofBMIvariance, respec-
tively). Taken together, these observations suggest that psy-
chiatric illness and/or potentially weight gain–inducing psy-
chotropic drugs might play a role in genetically mediated
energy homeostasis and that the association of CRTC1 vari-
ants with BMI in the general population is much weaker.
The stronger association found inwomen comparedwith
men could be caused by a differential role of the leptin-
mediating satiety pathway in the enhancement of CRTC1 ac-
tivity.Womenhavemuchhigher leptin levels thanmen,53 and
Table 2. Association of rs6510997C>TWith Body FatMass in the CoLaus General Adult Sample Studya
Sample
Fat Mass, kg, Adjusted
Mean (SE) Sample Size
P Value
for
Linear
Trend
Explained
Variance,b
%
CoLaus
CC 21.84 (0.11) 3395
CT 21.48 (0.16) 1744
TT 21.21 (0.47) 199 .03 0.06
Men only
CC 19.92 (0.14) 1614
CT 19.81 (0.19) 814
TT 19.08 (0.55) 102 .23 0.03
Women only
CC 23.57 (0.17) 1781
CT 22.99 (0.24) 930
TT 23.08 (0.75) 97 .07 0.08
Women, premenopausal
CC 20.83 (0.26) 767
CT 20.00 (0.36) 389
TT 18.90 (1.18) 36 .02 0.33
Women, postmenopausal
CC 25.57 (0.24) 1014
CT 25.21 (0.32) 541
TT 25.98 (0.96) 61 .66 0.01
Women, premenopausal, no contraceptive pill
CC 20.73 (0.29) 626
CT 20.09 (0.41) 314
TT 19.29 (1.37) 28 .12 0.18
Women, premenopausal, with contraceptive pill
CC 21.29 (0.55) 141
CT 19.50 (0.75) 75
TT 17.87 (2.30) 8 .02 1.34
No drug
CC 19.38 (0.16) 1357
CT 19.08 (0.22) 710
TT 19.00 (0.63) 88 .26 0.05
Any drug
CC 23.51 (0.15) 2038
CT 23.07 (0.22) 1034
TT 22.75 (0.66) 111 .06 0.07
Drugs possibly increasing weightc
CC 23.87 (0.28) 630
CT 23.13 (0.38) 348
TT 22.29 (1.15) 38 .06 0.24
Other drugs
CC 23.32 (0.18) 1408
CT 23.09 (0.26) 686
TT 23.16 (0.80) 73 .52 0.01
a Data are fat mass (in kilograms)
adjusted for age, sex (whenever
appropriate), height, leanmass, and
smoking.
b Explained variance by the
polymorphism percentage.
c Drugs are listed in eTable 1 in
Supplement.
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female sex was found to predict stronger weight gain during
antipsychotic treatment.54 Interestingly, studies examining
the influence of polymorphisms in the leptin or leptin
receptor genes on weight increases induced by antipsychot-
ics also showed sex-specific differences.55,56 CRTC1 trans-
genic animal models did not show sex differences in body
weight or obesity.29,30 However, mice used in these studies
were knockout for CRTC1, while the present polymorphism
is associated with decreased BMI and/or fat mass, suggest-
ing a possible gain of function that could interact with leptin
and show differences between males and females. The dif-
ference found between women in the 2 age groups, with the
protective effect of the minor allele (rs3746266 G or
rs6510997 T) being attenuated with age, suggests a complex
mechanism with potential interactions with gonadal sex
hormones. Interestingly, although the sample size was
small, women taking oral contraceptives appear to be more
protected against fat accumulation when carrying the minor
allele of rs6510997C>T than the other premenopausal
women. Thus, estrogen levels appear to modulate the effect
of the CRTC1 polymorphism on fat accumulation. A hypo-
thetical mechanism of the effect of CRTC1 and its interac-
tion with sex hormones is presented in eFigure 2 in Supple-
ment. A recent meta-analysis of genome-wide association
studies reported an association of an intronic SNP of CRTC1
(rs10423674A>C) with the age of menarche,57 supporting a
potential interaction between sex hormones and CRTC1.
Becausemost of the patients had a longhistory of psychi-
atric illness, they were not drug naive, having previously re-
ceived and experienced weight gain due to multiple treat-
ments before the current one, ahighprevalenceof overweight
and obesity was visible at the initiation of the current treat-
ment.Thus,BMIat thebeginningof the current treatmentwas
already different between CRTC1 genotypes, with the G car-
riers showing lowerBMI.However, no significant influenceof
CRTC1 genotypes was observed on BMI before the initiation
of the firstpsychotropic treatment in samples 1 and3.This sug-
gests thatweight gain induced by the psychotropic treatment
contributes at least partially to the strong influence of CRTC1
genotypes on BMI in psychiatric patients. Interestingly, a re-
cent study showed an influence of aCRTC3polymorphismon
BMI only in a population with a high prevalence of obesity.
CRTC3 is mainly expressed in adipose tissue and has been
shown to be involved in energy balance inmice.58 Higher en-
ergy expenditure and less adipose tissuemasswere observed
inCRTC3-knockoutmicecomparedwith their littermates, lead-
ing to lowerweight gainunder a hypercaloric diet. TheCRTC3
rs8033595polymorphismwas associatedwith several anthro-
pometric indices in 2MexicanAmerican populations (n = 779
and n = 987), with a high prevalence of obesity, but this find-
ing could not be replicated in populationswith other ethnici-
ties with lower prevalence of obesity.58
Several limitations of this study need to be acknowl-
edged.Most patientswerenot drugnaive andhad alreadyde-
velopedweight gain due to previous treatments. Itwas there-
fore not possible to determine with certainty whether the
strong association ofCRTC1 genotypeswith BMI and fatmass
in psychiatric populations was due to the psychiatric illness
and/or to the pharmacological treatment. Extensive hor-
monal measurements were not available for our samples, so
the role of sex hormones on the association ofCRTC1 variants
with adiposity could not be explored. Baseline self-reported
weights before the current treatment were only available in a
subset of the patients. It was only considered when mea-
sured weight was not available, though in the patients for
whombothdatawereavailable, a strongcorrelationwas found
between self-declarations and the medical files. Weights be-
fore the first psychotropic treatmentwere only self-reported.
Inaddition, thepotential influenceofotherenvironmental and
social factors on weight could not be accounted for because
of the naturalistic design of the psychiatric studies. However,
the fact that the resultswere replicated in 2 independent psy-
chiatric samples and in 2 large population-based samples
strengthens thevalidityof ourdata. This study includedwhite
people and results cannot be generalized to other ethnic
groups. Finally, these results do not allow the determination
of whether the rs3746266A>G genetic polymorphism, al-
though leading to an amino acid change, is the causative vari-
ant or merely a proxy of 1 or more yet unidentified variants.
Furtherstudiesareneededtoelucidate thebiochemicalmecha-
nisms underlying the observed associations.
To our knowledge, this is the first study showing an asso-
ciationofCRTC1polymorphismswithBMI and fatmass inhu-
mans. Our results suggest that CRTC1 plays an important role
in the high prevalence of overweight and obesity observed in
psychiatricpatients.Besides,CRTC1 couldplaya role in thege-
netics of obesity in the general population, thereby increas-
ing our understanding of the multiple mechanisms influenc-
ing obesity. Finally, the strong associations of CRTC1 variants
with adiposity in women younger than 45 years support fur-
ther research on the interrelationship between adiposity and
the reproductive function.
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